Accompanying NME in HER2 positive breast cancer was more frequently had positive pathologic results than HER2 negative breast cancers (84.6% [11 of 13] vs. 40.7% [11 of 27], P = .016). This evidence concerns the gene ERBB2 and breast cancer.